Company intelligence / Profile preview

VBHI

Cambridge, Massachusetts, United Statesvbhi.com ↗

Ownership: Private
Development stage: Commercial

Overview

VBI Vaccines developed virus-like particle-based vaccines targeting infectious diseases like hepatitis B and cancers such as glioblastoma. Its lead product, PreHevbrio® for hepatitis B prevention, was FDA-approved. The company also advanced immunotherapeutic candidates into clinical trials for glioblastoma. As of mid–2025, all commercial activities have ceased due to discontinuation of operations and a voluntary recall was issued for PreHevbrio® within expiry dates.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Vaccine
Industry: Biotech

Partnerships

Collaborations with academic institutionsCollaborations with government agencies

Beyond the preview

Go deeper on VBHI.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VBHI.

Explore the full profile